利益冲突利益冲突 无
参考文献
[1]SiddellS, MyintS. Coronaviruses: Viral and other infections of the human respiratory tract[M]. Berlin: Springer Netherlands,1996.
[2]ZhouP, FanH, LanT, et al. Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin[J]. Nature, 2018, 556(7700):255-258.DOI: 10.1038/s41586-018-0010-9. https://www.nature.com/articles/s41586-018-0010-9
蝙蝠是类 SARS 冠状病毒的天然宿主Bats Are Natural Reservoirs of SARS-Like Coronaviruses https://www.science.org/doi/10.1126/science.1118391
血管紧张素转换酶 2 是 SARS 冠状病毒的功能受体Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus https://www.nature.com/articles/nature02145
[3]Wikipedia. Coronavirus[EB/OL]. (2018-05-26) [2018-07-19]. https://it.wikipedia.org/wiki/Coronavirus.
[4]郭丽,王健伟,洪涛. 冠状病毒分子生物学研究进展[J]. 病毒学报,2003, 19(4):376-380. DOI: 10.3321/j.issn:1000-8721.2003.04.016.GuoL, WangJW, HongT. Progress of research on the molecular biology of the coronavirus[J]. Chinese Journal of Virology, 2003, 19(4):376-380. DOI: 10.3321/j.issn:1000-8721.2003.04.016. (in Chinese)
[5]李广兴,潘龙. 冠状病毒基因组结构和相关蛋白研究进展[J]. 东北农业大学学报,2013,44(9):149-154. DOI: 10.3969/j.issn.1005-9369.2013.09.027.LiGX, PanL. Research development of genome structure and related protein of coronavirus[J]. Journal of Northeast Agricultural University, 2013, 44(9):149-154. DOI: 10.3969/j.issn.1005-9369.2013.09.027. (in Chinese)
[6]JinL,CebraCK,BakerRJ,et al. Analysis of the genome sequence of an alpha coronavirys[J]. Virology, 2007, 365(1): 198-203. DOI: 10.1016/j.virol.2007.03.035.
[7]VriesAAFD, HorzinekMC, RottierPJM, et al. The genome organization of the nidovirales:similarities and differences between arteri-,toro- and coronaviruses[J]. Seminars in Virology, 1997, 8(1):33-47.
[8]de GrootRJ,BakerSC,BaricR, et al. Coronaviridae. In: virus taxonomy: ninth report of the international committee on taxonomy of viruses[M]. San Diego: Elsevier Academic Press, 2012.
[9]CongYY,VerlhacP,ReggioriF. The interaction between Nidovirales and autophagy components[J]. Viruses, 2017, 9(7). Pii:E182. DOI: 10.3390/v9070182.
[10]ColemanCM, FriemanMB. Coronaviruses:Impoytant emerging human pathogens[J]. J Virol, 2014, 88(10):5209-5212. DOI: 10.1128/JVI.03488-13.
[11]LiF. Receptor recognition mechanisms of coronaviruses: a decade of structural studies[J]. J Virol, 2015, 89(4):1954-1964. DOI: 10.1128/JVI.02615-14.
[12]RajVS,MouH,SmitsSL,et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC[J]. Nature,2013, 495(7440):251-254. DOI: 10.1038/nature12005.
[13]YangY, DuL, LiuC, et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus[J]. Proc Natl Acad Sci U S A, 2014, 111(34):12516-12521. DOI: 10.1073/pnas.1405889111.
[14]DuL, ZhaoG, KouZ, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus middle east respiratory syndrome coronavirus as an essential target for vaccine development[J]. J Virol, 2013, 87(17):9939-9942. DOI: 10.1128/JVI.01048-13.
[15]DijkmanR, JebbinkMF, El IdrissiNB, et al. Human coronavirus NL63 and 229E seroconversion in children[J]. J Clin Microbiol, 2008, 46(7):2368-2373. DOI: 10.1128/JCM.00533-08.
[16]ChannappanavarR, PerlmanS. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology[J]. Semin Immunopathol, 2017, 39(5):529-539. DOI: 10.1007/s00281-017-0629-x.
[17]蒋虹,鲍琳琳,涂新明,等. SARS-CoV感染猴模型病毒学研究[J]. 医学动物防制,2006, 22(6): 409-411. DOI: 10.3969/j.issn.1003-6245.2006.06.007.JiangH, BaoLL, TuXM, et al. The SARS virus isolation from monkeys infected with SARS-CoV[J]. Journal of Medical Pest Control, 2006, 22(6): 409-411. DOI: 10.3969/j.issn.1003-6245.2006.06.007.(in Chinese)
[18]KuikenT,Fouchier,RA, SchuttenM, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome[J]. Lancet, 2003, 362(9380):263-270. DOI: 10.1016/S0140-6736(03)13967-0.
[19]孙金福,涂长春. SARS-CoV的来源及其种间传播分子学进化基础[J]. 中国人兽共患病学报,2007,23(6):625-627.SunJF, TuCC. The source of SARS-CoV and the molecular evolutionary basis of its interspecies transmission[J]. Chinese Journal of Zoonoses, 2007, 23(6):625-627. (in Chinese)
[20]StockmanLJ, BellamyR, GarnerP, et al. SARS: systematic review of treatment effects[J]. PLoS Med, 2006, 3(9):e343. DOI: 10.1371/journal.pmed.0030343.
[21]Carbajo-LozoyaJ, MüllerMA, KalliesS, et al. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506[J]. Virus Res, 2012, 165(1):112-117. DOI: 10.1016/j.virusres.2012.02.002.
[22]LeungTF, ChanPK, WongWK, et al. Human coronavirus NL63 in children:epidemiology,disease spectrum, and genetic diversity[J]. Hong Kong Med J, 2012, 18 (Suppl 2):27-30.
[23]CuiLJ,ZhangC,ZhangT, et al. Human coronaviruses HCoV-NL63 and HCoV-HKU1 in hospitalized children with acute respiratory infections in Beijing, China[J]. Adv Virol, 2011, 2011:129134. DOI: 10.1155/2011/129134.
[24]段招军,黄灿平,瞿小旺,等. 中国内陆发现HCoV-HKU1感染及N和S蛋白基因序列分析[J]. 病毒学报,2006, 22(4):241-247. DOI: 10.3321/j.issn:1000-8721.2006.04.001.DuanZJ, HuangCP, QuXW, et al. Phylogenetic and Sequence Analyses of the N and S Genes of Coronavirus HKU1, a Novel Human Coronavirus in Mainland China[J]. Chinese Journal of Virology, 2006, 22(4):241-247. DOI: 10.3321/j.issn:1000-8721.2006.04.001. (in Chinese)
[25]WooPC, LauSK, ChuCM,et al. Characterization and complete genome sequence of a novel coronavirus, coronavirusHKU1, from patients with pneumonia[J]. J Virol, 2005, 79(2):884-895. DOI: 10.1128/JVI.79.2.884-895.2005.
[26]World Heath Organization. MERS situation update, April 2018[EB/OL]. (2018-04) [2018-07-19]. http://www.emro.who.int/pandemic ... te-april-2018.html.
[27]World Heath Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) summary and literature update-as of 11 June 2014[EB/OL]. (2014-06-11) [2018-07-19]. http://www.who.int/csr/disease/c ... _20140611.pdf?ua=1.
[28]王年爽. 中东呼吸综合征冠状病毒MERS-CoV的受体识别机制研究[C]. 北京:清华大学,2014.WangNS. Receptor Recognition Mechanism of Middle East Respiratory Syndrome Coronavirus MERS-CoV[C]. Beijing: Tsinghua University, 2014. (in Chinese)
[29]OhMD, ParkWB, ParkSW, et al. Middle east respiratory syndrome coronavirus:what we learned from the 2015 outbbreak in the Republic of Korea[J]. Korean J Inter Med, 2018, 33(2):233-246. DOI: 10.3904/kjim.2018.031.
[30]MemishZA, MishraN, OlivalKJ, et al. Middle east respiratory syndrome coronavirus in bats, Saudi Arabia[J].Emerg Infect Dis, 2013, 19(11):1819-1823. DOI: 10.3201/eid1911.131172.
[31]AzharEI, El-KafrawySA, FarrajSA, et al. Evidence for camel-to-human transmission of MERS coronavirus[J]. N Engl J Med, 2014, 370(26):2499-2505. DOI: 10.1056/NEJMoa1401505.
[32]AssiriA, Al-TawfiqJA, Al-RabeeahAA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study[J]. Lancet Infect Dis, 2013, 13(9):752-761. DOI: 10.1016/S1473-3099(13)70204-4.
[33]AjlanAM, AhyadRA, JamjoomLG, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings[J]. AJR Am J Roentgenol, 2014, 203(4): 782-787. DOI: 10.2214/AJR.14.13021.
[34]DuL, YangY, ZhouY,et al. MERS-CoV spike protein: a key target for antivirals[J]. Expert Opin Therapeutic Targets,2017,21(2):131-143. DOI: 10.1080/14728222.2017.1271415.
[35]李行舟,周幸波,钟武. 中东呼吸综合征的临床治疗和小分子治疗药物研究进展[J]. 国际药学研究杂志,2015,42(3):296-302. DOI: 10.13220/j.cnki.jipr.2015.03.002.LiXZ, ZhouXB, ZhongW. Clinical treatment and small molecular drugs for anti MERS-CoV:research advances[J]. J Int Pharm Res, 2015, 42(3): 296-302. DOI: 10.13220/j.cnki.jipr.2015.03.002. (in Chinese)
[36]HosoyaM, MatsuyamaS, BabaM,et al. Effects of protease inhibitors on replication of various myxoviruses[J]. Antimicrob Agents Chemother, 1992, 36 (7) :1432-1436.
[37]YamamotoM,MatsuyamaS, LiX,et al. Identification of nafamostat as a potent inhibitor of middle east respiratory ryndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay[J]. Antimicrob Agents Chemother, 2016, 60(11): 6532-6539. DOI: 10.1128/AAC.01043-16.
[38]TaylorR, KotianP,WarrenT, et al. BCX4430-a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease[J]. J Infect Public Health, 2016, 9(3):220-226.DOI: 10.1016/j.jiph.2016.04.002.
[39]SheahanTP, SimsAC, GrahamRL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses[J]. Sci Transl Med, 2017, 9(396). Pii: eaal3653. DOI: 10.1126/scitranslmed.aal3653.
[40]WarrenTK,JordanR,LoMK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys[J]. Nature, 2016, 531(7594):381-385. DOI: 10.1038/nature17180. https://www.nature.com/articles/nature17180
[41]DiamondMS, ZachariahM, HarrisE. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA[J]. Virology, 2002, 304 (2):211-221.
[42]TakhampunyaR, UbolS, HoungHS, et al. Inhibition of dengue virus replication by mycophenolic acid and ribavirin[J]. J GenVirol,2006,87(Pt 7):1947-1952. DOI: 10.1099/vir.0.81655-0.
[43]ChengKW,ChengSC, ChenWY,et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus[J]. Antiviral Res, 2015, 115:9-16. DOI: 10.1016/j.antiviral.2014.12.011.